List of adverse effects of ribavirin

Temporary visual loss after treatment with ribavirin (and pegylated interferon alfa-2a). Both eyes at admission and 5 years later

List of adverse effects of ribavirin by frequency.[1][2][3]

## Contents

* 1 Very common (>10% frequency)
* 2 Common (1-10% frequency)
* 3 Uncommon (0.1-1% frequency)
* 4 Rare (0.01-0.1% frequency)
* 5 Very rare (<0.01% frequency)
* 6 Unknown frequency
* 7 References

## Very common (>10% frequency)[edit | edit source]

* Viral pharyngitis
* Anemia
* Neutropenia
* Appetite loss
* Weight loss
* Depression
* Anxiety
* Emotional lability
* Insomnia
* Headache
* Dizziness
* Dry mouth
* Concentration impaired
* Shortness of breath
* Nausea
* Vomiting
* Diarrhea
* Abdominal pain
* Hair loss
* Dry skin
* Itchiness
* Rash
* Joint aches and pains
* Muscle aches and pains
* Musculoskeletal pain
* Fatigue
* Rigors
* Fever
* Influenza-like illness
* Muscle weakness
* Irritability

## Common (1-10% frequency)[edit | edit source]

* Hemolytic anemia
* Leukopenia
* Thrombocytopenia
* Lymphadenopathy
* Lymphopenia
* Hypothyroidism
* Hyperthyroidism
* Hyperglycemia
* Hyperuricemia
* Hypocalcemia
* Dehydration
* Increased appetite
* Palpitation
* Tachycardia
* Hypotension
* Hypertension
* Flushing
* Hepatomegaly
* Jaundice
* Hyperbilirubinemia
* Arthritis
* Back pain
* Muscle spasms
* Pain in extremity
* Micturition frequency
* Polyuria
* Urine abnormality
* Chest pain
* Chest discomfort
* Peripheral edema
* Malaise
* Feeling abnormal
* Thirst
* Cardiac murmur
* Neoplasm formation
* Sexual disturbances (including erectile dysfunction, prostatis, amenorrhea, etc.)
* Skin disturbances (including acne, eczema, psoriasis, etc.)
* Gastrointestinal disturbances (including mouth ulcers, indigestion, diarrhea, constipation, etc.)
* Upper respiratory tract disturbances (including nosebleeds, nasal/sinus congestion, etc.)
* Visual and hearing disturbances (including tinnitus, blurred vision, etc.)
* Neurologic disturbances (including memory loss, migraines, incoordination, sensory distortions, etc.)
* Psychiatric disturbances (including suicidal ideation and psychosis)
* Infections (including sinusitis, the flu, sepsis, UTIs, etc.)

## Uncommon (0.1-1% frequency)[edit | edit source]

* Hypersensitivity
* Diabetes mellitus
* Hypertriglyceridemia
* Neuropathy
* Heart attack
* Mouth pain
* Pancreatitis
* Bone pain
* Facial edema

* Immediately life-threatening psychiatric disturbances, including suicide attempts and hallucinations

## Rare (0.01-0.1% frequency)[edit | edit source]

* Pneumonia
* Sarcoidosis
* Rheumatoid arthritis
* Bipolar episode
* Seizures
* Serious eye complications
* Arrhythmia
* Cardiomyopathy
* Vasculitis
* Ischemic colitis
* Rhabdomyolysis
* Myositis
* Kidney failure or insufficiency

## Very rare (<0.01% frequency)[edit | edit source]

* Aplastic anemia
* Suicide
* Stroke
* Polyneuropathy
* Encephalopathy
* Cardiac ischemia
* Life-threatening lung complications
* Ulcerative colitis
* Liver failure
* Stevens–Johnson syndrome
* Toxic epidermal necrolysis
* Erythema multiforme
* Nephrotic syndrome

## Unknown frequency[edit | edit source]

* Pure red cell aplasia
* Idiopathic thrombocytopenic purpura
* Thrombotic thrombocytopenic purpura
* Mania
* Vogt–Koyanagi–Harada disease
* Systemic lupus erythematosus
* Vasculitis
* Hives
* Angioedema
* Bronchoconstriction
* Anaphylaxis
* Homicidal ideation
* Mental status change
* Facial palsy
* Mononeuropathies
* Pericardial effusion
* Pericarditis
* Periodontal disorder

## References[edit | edit source]

1. ↑ "PRODUCT INFORMATION REBETOL (RIBAVIRIN) CAPSULES" (PDF). TGA eBusiness Services. Merck Sharp & Dohme (Australia) Pty Limited. 29 April 2013. Archived from the original on 16 August 2017. Retrieved 23 February 2014.
2. ↑ "COPEGUS (RIBAVIRIN) TABLET, FILM COATED [GENENTECH, INC]". DailyMed. Genentech, Inc. February 2013. Archived from the original on 12 October 2012. Retrieved 23 February 2014.
3. ↑ "Rebetol 200mg hard capsules - Summary of Product Characteristics". Merck Sharp & Dohme Limited. 27 January 2014. Archived from the original on 27 February 2014. Retrieved 23 February 2014.